iDeg-6
iDeg-6 is a molecular glue degrader that selectively targets IDO1, with a DC50 of 6.5 nM, an IC50 of 16 nM, and a Kd of 1.46 μM. iDeg-6 competes to bind the heme-binding site of apoprotein IDO1, promoting CRL2KLHDC3-mediated polyubiquitination of IDO1 and neddylation-modification-dependent proteasomal degradation. iDeg-6 reduces kynurenine production, abrogates the non-enzymatic pro-tumor migration function of IDO1, and inhibits tumor growth in immunodeficient mice. iDeg-6 can be used in studies of cancer, infection, and neurological diseases (such as melanoma).
For research use only. We do not sell to patients.
- Formula: C32H40N2O4S
- Molecular Weight:548.74
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
IDO1 6.5 nM (DC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BXPC-3 | DC50 |
6.5 nM
|
Half-maximal IDO1 protein degradation in IFN-γ-pretreated, washout BxPC3 cells after 24 h incubation measured via immunoblotting.
Half-maximal IDO1 protein degradation in IFN-γ-pretreated, washout BxPC3 cells after 24 h incubation measured via immunoblotting.
|
PMC11257573 |
| BXPC-3 | IC50 |
16 nM
|
Inhibition of kynurenine formation via indoleamine-2,3-dioxygenase 1 enzymatic activity in IFN-γ-stimulated BxPC3 cells incubated for 48 h, measured by Kyn assay utilizing p-DMAB.
Inhibition of kynurenine formation via indoleamine-2,3-dioxygenase 1 enzymatic activity in IFN-γ-stimulated BxPC3 cells incubated for 48 h, measured by Kyn assay utilizing p-DMAB.
|
41501556 |
| BXPC-3 | IC50 |
14 nM
|
Inhibition of kynurenine production in human BxPC3 cells incubated for 48 h with interferon gamma, L-tryptophan, and iDeg-6 measured via cell-based kynurenine pathway inhibition assay.
Inhibition of kynurenine production in human BxPC3 cells incubated for 48 h with interferon gamma, L-tryptophan, and iDeg-6 measured via cell-based kynurenine pathway inhibition assay.
|
41310997 |
In Vitro
iDeg-6 potently inhibits kynurenine formation in IFN-γ-stimulated BxPC3 cells with an IC50 of 16 nM[1].
iDeg-6 (0.5-10000 nM; 24 h) dose-dependently depletes IDO1 protein in IFN-γ-pretreated, washout BxPC3 cells with a DC50 of 6.5 nM and a Dmax of 70% at 100 nM[1].
iDeg-6 (0.01-10 µM; 24 h) dose-dependently depletes IDO1 protein in SKOV-3 cells over 24 h of incubation[1].
iDeg-6 (0.01-1 µM; 24 h) dose-dependently depletes IDO1 protein in BT549 cells over 24 h of incubation[1].
iDeg-6 (1-100 nM; 24 h) mediated IDO1 protein depletion in IFN-γ-pretreated, washout wildtype U2OS cells is dependent on KLHDC3, as knockout of KLHDC3 abolishes the degradation and elevates baseline IDO1 levels[1].
iDeg-6 (10-3-105 nM) mediated IDO1 depletion in KBM7-BFP-IDO1 cells is dependent on KLHDC3, as knockout of KLHDC3 abolishes the degradation and elevates baseline IDO1 levels[1].
iDeg-6 (10-10000 nM)-bound full-length IDO1 binds to CRL2KLHDC3 with similar high affinity as apo-IDO1, with an IC50 of 118 nM in a competitive ubiquitination assay[1].
iDeg-6 potently inhibits recombinant human IDO1 enzymatic activity in vitro with an IC50 of 1.6 µM[1].
iDeg-6 (48 h) potently inhibits IDO1 enzymatic activity in IFN-γ-stimulated BxPC3 cells with an IC50 of 16 nM[2].
iDeg-6 (0.5-10000 nM; 24 h) dose-dependently depletes IDO1 protein in IFN-γ-pretreated BxPC3 cells with a DC50 of 6.5 nM and a Dmax of 70% at 100 nM[2].
iDeg-6 (0.01-1 μM; 24 h) dose-dependently depletes IDO1 protein in BT549 cells after 24 h of treatment[2].
iDeg-6 (1-100 nM; 24 h) dose-dependently depletes IDO1 protein in IFN-γ-pretreated wild-type U2OS cells after 24 h of treatment, and this degradation is dependent on the E3 ligase KLHDC3[2].
iDeg-6 (90 min) potently inhibits in vitro IDO1 enzymatic activity with an IC50 of 1.6 μM[2].
iDeg-6 (50 μM; 3 h) stabilizes recombinant human IDO1 protein in vitro, as measured by nanoDSF, more effectively than iDeg-1, iDeg-2, and iDeg-3[2].
iDeg-6 (100 μM; 3 h) displaces haem from recombinant human holo-IDO1 in vitro, as measured by UV-vis spectroscopy, more effectively than iDeg-1, iDeg-2, and iDeg-3[2].
iDeg-6 (14 nM; 48 h) inhibits kynurenine production in BxPC3 cells with an IC50 of 14 nM[3].
iDeg-6 (14 μM; 45 min) shows weak inhibition of recombinant human IDO1 enzymatic activity, with 40% inhibition at 14 μM and an IC50 >14 μM[3].
iDeg-6 (6.5-100 nM; 24 h) potently degrades IDO1 protein in IFN-γ-stimulated cells with a DC50 of 6.5 nM and 74% maximum degradation at 100 nM[3].
iDeg-6 (25 μM) binds to recombinant human IDO1 with a Kd of 1.46 μM in an enthalpy-driven interaction[3].
iDeg-6 (1 μM; 24 h (pre-conditioning)) reduces the migratory capacity of SKOV-3 cells by depleting IDO1, targeting its non-enzymatic protumorigenic function[2].
iDeg-6 (10 μM; 4 h) selectively reduces IDO1 protein levels in SKOV-3 cells, with no other targeted protein degradation detected among 4607 analyzed proteins[3].
iDeg-6 (6.5-16 nM; 100 nM) potently inhibits IDO1 activity in BxPC3 cells with an IC50 of 16 nM and induces IDO1 protein degradation with a DC50 of 6.5 nM and 70% maximum degradation at 100 nM via recruitment of the KLHDC3 E3 ligase[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:IFN-γ-pretreated, washout BxPC3 cells
-
Concentration:0.5-10000 nM
-
Incubation Time:24 h
-
Result:Dose-dependently reduced IDO1 protein levels, with a Dₘₐₓ of 70% at 100 nM and a DC50 of 6.5 nM.
-
Cell Line:SKOV-3 cells
-
Concentration:0.01-10 µM
-
Incubation Time:24 h
-
Result:Reduced IDO1 protein levels in a dose-dependent manner.
-
Cell Line:BT549 cells
-
Concentration:0.01-1 µM
-
Incubation Time:24 h
-
Result:Reduced IDO1 protein levels in a dose-dependent manner.
-
Cell Line:wildtype and KLHDC3 knockout U2OS cells (IFN-γ-pretreated with washout)
-
Concentration:1-100 nM
-
Incubation Time:24 h
-
Result:Dose-dependently reduced IDO1 protein levels in wildtype U2OS cells.
Failed to reduce IDO1 protein levels in KLHDC3 knockout U2OS cells, which remained elevated compared to wildtype cells.
-
Cell Line:IFN-γ-pretreated BxPC3 cells
-
Concentration:0.5-10000 nM
-
Incubation Time:24 h
-
Result:Dose-dependently reduced IDO1 protein levels, achieving a maximal achievable degradation (Dₘₐₓ) of 70% at 100 nM, with a half-maximal degradation concentration (DC50) of 6.5 nM.
-
Cell Line:unstimulated and IFN-γ-stimulated SKOV-3 cells
-
Concentration:0.01-10 μM (unstimulated SKOV-3); 0.01-1 μM (IFN-γ-stimulated SKOV-3)
-
Incubation Time:24 h
-
Result:Dose-dependently reduced IDO1 protein levels in both unstimulated and IFN-γ-stimulated SKOV-3 cells.
-
Cell Line:BT549 cells
-
Concentration:0.01-1 μM
-
Incubation Time:24 h
-
Result:Dose-dependently reduced IDO1 protein levels.
-
Cell Line:wild-type and KLHDC3 knockout U2OS cells
-
Concentration:1-100 nM
-
Incubation Time:24 h
-
Result:Dose-dependently reduced IDO1 protein levels in wild-type U2OS cells, but this depletion was rescued in KLHDC3 knockout U2OS cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NSG immunodeficient[3]
-
Dosage:30 mg/kg
-
Administration:i.p.; twice daily; 18 days
-
Result:Inhibited SKOV-3 tumor growth significantly.
Showed no significant negative impact on body weight, with a slight body weight recovery observed.
Improved overall mouse survival significantly compared to vehicle control.
Chemical Information
-
Molecular Weight 548.74
-
Formula C32H40N2O4S
-
SMILES
C#CC1=CC=C(C=C1)NC(OC[C@@]23[C@H](C[C@@H]4C[C@]2([H])CN(C3)S(C5=C(C)C=C(C(C)(C)C)C=C5)(=O)=O)C4(C)C)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)